Sharp Mesa Vista Hospital is enrolling both men and women ages 55 to 85 for studies of investigational medicines for Alzheimer's disease. To qualify, you must:

• Attend study visits at Sharp Mesa Vista Hospital's Clinical Research Center
• Have a caregiver (spouse, relative or health care aide) who can accompany you to study visits and help monitor your study progress

Mild Alzheimer's clinical trials.

NAVIGATE-AD — a study for people who have been experiencing worsening memory problems, or who may have been diagnosed with mild Alzheimer’s disease. As Alzheimer’s disease progresses, a protein called tau builds up inside the brain. The NAVIGATE-AD study will ask what effect an oral investigational study drug has on the protein build up and the effect on Alzheimer’s disease symptoms. Learn more about this study.

DAYBREAK-ALZ — the study will last eight weeks to see if you qualify, plus three years of treatment, then four weeks of follow-up. The study drug is a tablet, to be taken once a day. The tablet will contain either a lower dose of the study drug, a higher dose of the study drug, or a placebo, depending on which group you are assigned to. A placebo tablet is one that contains no active ingredients. Learn more about this study.

ReCOGNITION — this study is for people currently taking medication to treat mild Alzheimer's disease. Study will last for six weeks, and participants will receive one of three doses of either the study drug (Piromelatine) or a placebo. Participants will continue taking their prescribed medication during the study. The study will determine if Piromelatine will improve slow wave sleep and, additionally, will also improve memory and limit the effects of Alzheimer's. Learn more about this study.

How to enroll.

To learn more or to enroll in a clinical trial, call 858-836-8350 or send us an email.